Business
HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association
HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at ...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n \n \n \n HLS Therapeutics Highlights Key Data on the Late Breaking RESPECT-EPA Study Presented at the American Heart Association\n \n \n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n \n \n \n \n \n \n Canada NewsWire\n \n \n \n \n \n Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore Cardiovascular\n \n Risk Reduction Benefits of Eicosapentaenoic Acid (\"EPA\") for Patients\n \n \n \n \n \n TORONTO\n \n \n ,\n \n \n Nov. 7, 2022\n \n \n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, today highlighted key data presented at the American Heart Association (\"AHA\") 2022 Scientific Sessions relevant to VASCEPA\n \n ®\n \n (icosapent ethyl) related to RESPECT-EPA, A Randomized Trial for Evaluation in Secondary Prevention Efficacy of Combination Therapy - Statin and Eicosapentaenoic Acid (\"EPA\").\n \n \n \n RESPECT-EPA Third Study to Show Cardiovascular Benefit Consistent with REDUCE-IT\n \n ®\n \n and JELIS\n \n \n \n The RESPECT-EPA clinical trial is an independent study funded by the Japanese Heart Foundation. In 2005, the Japan EPA Lipid Intervention study (\"JELIS\") first demonstrated a beneficial effect of highly purified EPA on cardiovascular outcomes in patients with or without coronary artery disease (\"CAD\"). In 2019, Amarin Corporation (NASDAQ: AMRN) published the positive results of its double-blind placebo-controlled study REDUCE-IT in patients with cardiovascular risk and elevated TG levels. And now, RESPECT-EPA is the third study that demonstrated the value of highly purified EPA in reducing cardiovascular outcomes in patients with CAD.\n \n \n The late breaking data presented at AHA using 1.8 grams per day of purified EPA is consistent with the substantial body of evidence from the REDUCE-IT and JELIS trials, which showed that highly purified prescription EPA plus statin significantly reduces the risk of cardiovascular events in high- and very high-risk statin-treated patients.\n \n \...